Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

Here are five storylines from the past year that we think defined Chicago's startup ecosystem in 2024 and will further shape ...

Cytrellis Biosystems, Inc., a pioneer in novel medical aesthetic solutions, today announced the launch of the updated ...